Grifols SA (GIFLF) is the 29th largest of 300 Biotechnology companies by market capitalisation, at 7.54 Bn, behind Immunovant, Inc. at 7.66 Bn. It trades on a P/E of 29.70, 71% above the peer median of 17.36. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 203.97 Bn | 23.33 | 5.35 | 189.99 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 178.74 Bn | -61.74 | 5.87 | 175.56 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 130.73 Bn | 29.68 | 10.39 | 122.88 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 80.42 Bn | 18.58 | 5.18 | 72.42 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 60.40 Bn | 35.21 | 11.56 | 55.21 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 57.65 Bn | -18.30 | 25.88 | 52.52 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 33.37 Bn | 43.08 | 6.95 | 30.07 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.15 Bn | 38.52 | 3.21 | 30.86 Bn |
| 9 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.58 Bn | -19.93 | 2,708.44 | 29.58 Bn |
| 10 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 28.06 Bn | -32.06 | 24.67 | 26.90 Bn |
| 11 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 23.43 Bn | -13.75 | 7.58 | 9.77 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.01 Bn | 18.47 | 11.30 | 15.07 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.59 Bn | -48.86 | 12.14 | 14.75 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.10 Bn | -20.39 | 19.78 | 13.38 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.63 Bn | — | — | 12.94 Bn |
| 16 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.67 Bn | 173.60 | 3.72 | 11.79 Bn |
| 17 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.59 Bn | 30.44 | 7.57 | 12.36 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.93 Bn | -43.86 | 17.83 | 10.33 Bn |
| 19 | AAVXF | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 20 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 21 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.78 Bn | 88.55 | 34.67 | 9.78 Bn |
| 22 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.77 Bn | -25.62 | — | 9.01 Bn |
| 23 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.04 Bn | -42.57 | 10.34 | 6.98 Bn |
| 24 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.56 Bn | -8.10 | — | 8.56 Bn |
| 25 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.45 Bn | -8.51 | 50.95 | 8.09 Bn |
| 26 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.70 Bn | -43.04 | — | 7.70 Bn |
| 27 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.67 Bn | 17.36 | 9.59 | 6.99 Bn |
| 28 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.66 Bn | -14.23 | — | 7.66 Bn |
| 29 | GIFLF | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 30 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.25 Bn | -17.96 | — | 7.25 Bn |
| 31 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.16 Bn | -34.08 | 29.86 | 6.83 Bn |
| 32 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.38 Bn | -28.45 | 1,023.83 | 6.38 Bn |
| 33 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.35 Bn | -708.81 | 4,560.40 | 6.35 Bn |
| 34 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.22 Bn | -7.23 | 10.07 | 5.79 Bn |
| 35 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.93 Bn | 73.51 | 7.05 | 5.40 Bn |
| 36 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.85 Bn | -16.14 | — | 5.85 Bn |
| 37 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.83 Bn | — | — | 4.10 Bn |
| 38 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.72 Bn | 29.02 | 19.70 | 4.37 Bn |
| 39 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.72 Bn | -15.45 | — | 5.72 Bn |
| 40 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.48 Bn | 14.32 | 5.43 | 3.25 Bn |
| 41 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.15 Bn | -29.28 | 1,026.61 | 4.98 Bn |
| 42 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.98 Bn | -17.34 | — | 4.98 Bn |
| 43 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.58 Bn | -20.90 | — | 4.58 Bn |
| 44 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.04 Bn | — | — | 3.64 Bn |
| 45 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.96 Bn | -7.74 | 1,097.69 | 3.96 Bn |
| 46 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.82 Bn | -13.36 | 368.95 | 3.82 Bn |
| 47 | TLPPF | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.72 Bn | -521.64 | 4.64 | 3.43 Bn |
| 48 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.71 Bn | -6.94 | — | 3.71 Bn |
| 49 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.60 Bn | -35.22 | 66.98 | 2.59 Bn |
| 50 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.53 Bn | -29.06 | — | 3.53 Bn |
| 51 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.46 Bn | -15.72 | 14.78 | 2.63 Bn |
| 52 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.34 Bn | -20.26 | 50.40 | 3.34 Bn |
| 53 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.13 Bn | 109.81 | 6.74 | 2.89 Bn |
| 54 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | -6.75 | 26.54 | 2.40 Bn |
| 55 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.00 Bn | -5.80 | — | 3.00 Bn |
| 56 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.88 Bn | -9.38 | 18,250.52 | 2.88 Bn |
| 57 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.82 Bn | -27.03 | — | 2.82 Bn |
| 58 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.80 Bn | -10.37 | 593.06 | 2.28 Bn |
| 59 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.79 Bn | -8.18 | 75.97 | 2.35 Bn |
| 60 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.73 Bn | -22.89 | 553.22 | 2.73 Bn |
| 61 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.70 Bn | -13.42 | — | 2.70 Bn |
| 62 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.70 Bn | -14.33 | 6.00 | 1.99 Bn |
| 63 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.48 Bn | -6.19 | — | 2.48 Bn |
| 64 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.36 Bn | -7.79 | 45.31 | 2.36 Bn |
| 65 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.30 Bn | -19.34 | 42.11 | 1.61 Bn |
| 66 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -2,975.41 | — | 2.29 Bn |
| 67 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.26 Bn | -11.37 | — | 1.89 Bn |
| 68 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | -5.58 | 31.40 | 2.23 Bn |
| 69 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | -67.43 | — | 2.19 Bn |
| 70 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.13 Bn | -34.28 | 11.31 | 2.03 Bn |
| 71 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.11 Bn | 12.67 | 4.11 | 1.97 Bn |
| 72 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | 0.17 | 0.33 | 0.60 Bn |
| 73 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -5.39 | 3.87 | 1.72 Bn |
| 74 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.06 Bn | -15.02 | 103.04 | 2.06 Bn |
| 75 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.05 Bn | -8.49 | — | 2.05 Bn |
| 76 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.00 Bn | -4.86 | 20.32 | 2.00 Bn |
| 77 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | -4.76 | 1,979.52 | 1.98 Bn |
| 78 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | -9.29 | 70.00 | 1.64 Bn |
| 79 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | -4.90 | — | 1.93 Bn |
| 80 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -12.82 | 51.79 | 1.65 Bn |
| 81 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.91 Bn | -3.26 | — | 1.64 Bn |
| 82 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.85 Bn | -11.31 | 17.59 | 1.47 Bn |
| 83 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | -7.06 | 5.86 | 1.78 Bn |
| 84 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -124.02 | 17.51 | 1.73 Bn |
| 85 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -6.58 | — | 1.19 Bn |
| 86 | GLPGF | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 87 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -12.96 | 1,329.57 | 1.73 Bn |
| 88 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.71 Bn | -3.29 | 31.11 | 1.16 Bn |
| 89 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -91.80 | 3.86 | 0.78 Bn |
| 90 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -26.62 | — | 1.30 Bn |
| 91 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.63 Bn | -195.13 | 949.13 | 1.63 Bn |
| 92 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -8.85 | 6.36 | 1.06 Bn |
| 93 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 94 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.56 Bn | -6.29 | 3.77 | 0.84 Bn |
| 95 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | -8.38 | — | 1.55 Bn |
| 96 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | -64.80 | 7.77 | 1.26 Bn |
| 97 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -9.89 | — | 1.47 Bn |
| 98 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -3.17 | 2.04 | 1.17 Bn |
| 99 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -9.11 | 20.12 | 1.17 Bn |
| 100 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.45 Bn | -13.67 | 72.51 | 1.45 Bn |
| 101 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.43 Bn | -9.27 | 49.70 | 0.79 Bn |
| 102 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -16.39 | — | 1.37 Bn |
| 103 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -8.37 | — | 1.37 Bn |
| 104 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.35 Bn | -9.67 | — | 1.35 Bn |
| 105 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | 77.80 | 34.56 | 1.33 Bn |
| 106 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.30 Bn | -8.27 | — | 1.30 Bn |
| 107 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.29 Bn | -10.67 | 827.71 | 1.09 Bn |
| 108 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -6.27 | — | 1.28 Bn |
| 109 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -4.24 | — | 1.26 Bn |
| 110 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -1.32 | — | 1.21 Bn |
| 111 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.19 Bn | -24.94 | — | 0.98 Bn |
| 112 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -4.85 | 141.23 | 0.67 Bn |
| 113 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.16 Bn | -26.62 | 2.95 | 1.05 Bn |
| 114 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.08 Bn | -18.83 | — | 1.08 Bn |
| 115 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.08 Bn | -10.53 | 45.00 | 1.08 Bn |
| 116 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.08 Bn | -7.03 | — | 1.08 Bn |
| 117 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 6.64 | 5.57 | 0.92 Bn |
| 118 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -67.86 | — | 0.89 Bn |
| 119 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.94 Bn | -118.02 | — | 0.94 Bn |
| 120 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.93 Bn | -4.61 | 14.28 | 0.57 Bn |
| 121 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.92 Bn | -3.49 | — | 0.39 Bn |
| 122 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.91 Bn | -13.49 | 3.72 | 0.61 Bn |
| 123 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | -15.90 | 1.96 | 0.60 Bn |
| 124 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 2.74 | 3.18 | 0.79 Bn |
| 125 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 20.79 | 8.43 | 0.49 Bn |
| 126 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -14.93 | 805.93 | 0.81 Bn |
| 127 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -3.88 | — | 0.79 Bn |
| 128 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | -125.46 | 2.34 | 0.62 Bn |
| 129 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.76 Bn | -9.52 | 92.22 | 0.76 Bn |
| 130 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | -9.52 | 39.42 | 0.39 Bn |
| 131 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | -6.98 | — | 0.70 Bn |
| 132 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | 3.02 | 1.71 | 0.59 Bn |
| 133 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | -5.69 | — | 0.66 Bn |
| 134 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | -6.04 | — | 0.59 Bn |
| 135 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -15.78 | 997.34 | 0.54 Bn |
| 136 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -8.26 | — | 0.61 Bn |
| 137 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -3.60 | 564.51 | 0.41 Bn |
| 138 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -11.95 | — | 0.58 Bn |
| 139 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -9.64 | 3.37 | 0.42 Bn |
| 140 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | 449.82 | 7.48 | 0.24 Bn |
| 141 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -317,522.54 | — | 0.56 Bn |
| 142 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | 59.61 | 1.75 | -0.01 Bn |
| 143 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | -9.16 | — | 0.55 Bn |
| 144 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | -6.42 | — | 0.55 Bn |
| 145 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.53 Bn | -11.94 | 13.75 | 0.48 Bn |
| 146 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -8.28 | — | 0.51 Bn |
| 147 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | -10.27 | 78.36 | 0.26 Bn |
| 148 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | -4.18 | — | 0.48 Bn |
| 149 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -10.60 | 8.53 | 0.18 Bn |
| 150 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -19.57 | — | 0.44 Bn |
| 151 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 15.44 | 2.00 | 0.37 Bn |
| 152 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 14.71 | 2.39 | 0.39 Bn |
| 153 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | -6.78 | 20.38 | 0.18 Bn |
| 154 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.48 | 12.94 | 0.20 Bn |
| 155 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -5.39 | — | 0.44 Bn |
| 156 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -15.03 | — | 0.44 Bn |
| 157 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | -3.11 | — | 0.43 Bn |
| 158 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -4.43 | 14.36 | 0.23 Bn |
| 159 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.30 | — | 0.25 Bn |
| 160 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.00 | — | 0.17 Bn |
| 161 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -4.05 | 38.38 | 0.18 Bn |
| 162 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -4.66 | — | 0.38 Bn |
| 163 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -4.03 | 36.52 | 0.38 Bn |
| 164 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -5.99 | 5.79 | 0.19 Bn |
| 165 | HMDCF | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | — | — | 0.39 Bn |
| 166 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -1.18 | 130.64 | 0.18 Bn |
| 167 | DMAC | DiaMedica Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -10.54 | — | 0.35 Bn |
| 168 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -4.27 | — | 0.34 Bn |
| 169 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -2.83 | — | 0.34 Bn |
| 170 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -6.68 | — | 0.34 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.81 | — | 0.32 Bn |
| 172 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -1.95 | 98.66 | 0.31 Bn |
| 173 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -4.74 | 8.48 | 0.24 Bn |
| 174 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 3.14 | 2.17 | 0.29 Bn |
| 175 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -1.72 | 60.73 | 0.28 Bn |
| 176 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -5.15 | 12.60 | 0.28 Bn |
| 177 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -2.43 | 3.07 | 0.11 Bn |
| 178 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 69.00 | — | 0.17 Bn |
| 179 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -3.96 | — | 0.27 Bn |
| 180 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -1.42 | 4.41 | 0.27 Bn |
| 181 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -3.26 | — | 0.27 Bn |
| 182 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -7.64 | — | 0.26 Bn |
| 183 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -9.19 | — | 0.26 Bn |
| 184 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -15.84 | 1.52 | 0.14 Bn |
| 185 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -3.00 | 4.49 | 0.09 Bn |
| 186 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -4.93 | 58.53 | 0.25 Bn |
| 187 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -2.94 | 102.15 | 0.13 Bn |
| 188 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -17.30 | — | 0.12 Bn |
| 189 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -6.69 | — | 0.24 Bn |
| 190 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -13.18 | — | 0.24 Bn |
| 191 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -2.69 | 17.01 | 0.06 Bn |
| 192 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 6.57 | 3.12 | 0.15 Bn |
| 193 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -10.08 | — | 0.22 Bn |
| 194 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.64 | 19.28 | 0.22 Bn |
| 195 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.44 | 6.70 | -0.04 Bn |
| 196 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.10 | — | 0.21 Bn |
| 197 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -2.03 | — | 0.21 Bn |
| 198 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 9.93 | 2.61 | 0.17 Bn |
| 199 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.56 | 4.06 | 0.10 Bn |
| 200 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -2.85 | — | 0.21 Bn |
| 201 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -3.08 | 14.68 | 0.17 Bn |
| 202 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -13.14 | 32.66 | 0.20 Bn |
| 203 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -3.18 | — | 0.17 Bn |
| 204 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -3.99 | 9.16 | 0.06 Bn |
| 205 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -1.19 | — | 0.19 Bn |
| 206 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 1.12 | — | 0.19 Bn |
| 207 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.79 | 8.07 | 0.16 Bn |
| 208 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.38 | — | 0.18 Bn |
| 209 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -11.87 | — | 0.16 Bn |
| 210 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.51 | 214.11 | 0.18 Bn |
| 211 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -5.57 | 2.72 | 0.04 Bn |
| 212 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -2.47 | — | 0.17 Bn |
| 213 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -1.05 | 60.09 | 0.17 Bn |
| 214 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -1.12 | 2.18 | -0.05 Bn |
| 215 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -4.81 | 32.39 | 0.16 Bn |
| 216 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -116.03 | — | 0.16 Bn |
| 217 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -2.51 | — | -0.02 Bn |
| 218 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -4.90 | 12.81 | 0.12 Bn |
| 219 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -9.93 | — | 0.13 Bn |
| 220 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -5.21 | — | 0.14 Bn |
| 221 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 | 1,775.44 | -0.04 Bn |
| 222 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.69 | — | 0.14 Bn |
| 223 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | — | — | -0.03 Bn |
| 224 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.35 | — | 0.13 Bn |
| 225 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.69 | — | 0.13 Bn |
| 226 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -1.86 | 43.44 | 0.13 Bn |
| 227 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -6.07 | 37.25 | 0.10 Bn |
| 228 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -3.83 | 1,264.33 | 0.13 Bn |
| 229 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.96 | — | 0.07 Bn |
| 230 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -4.41 | 119.97 | 0.12 Bn |
| 231 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -2.37 | — | 0.00 Bn |
| 232 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -6.55 | — | 0.11 Bn |
| 233 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.29 | — | 0.11 Bn |
| 234 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -4.63 | 12.87 | 0.06 Bn |
| 235 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -1.29 | — | 0.10 Bn |
| 236 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | — | — | -0.06 Bn |
| 237 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -2.16 | 60.89 | 0.10 Bn |
| 238 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -9.71 | — | 0.09 Bn |
| 239 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 2.11 | 148.65 | 0.10 Bn |
| 240 | TLPH | Talphera, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -6.70 | 94,589.89 | 0.09 Bn |
| 241 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.47 | — | 0.08 Bn |
| 242 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.96 | — | 0.09 Bn |
| 243 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -118.64 | — | 0.09 Bn |
| 244 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 2.67 | — | 0.08 Bn |
| 245 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.13 | — | 0.08 Bn |
| 246 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | — | — | 0.08 Bn |
| 247 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -3.55 | — | 0.08 Bn |
| 248 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.94 | 137.26 | 0.08 Bn |
| 249 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 9.63 | 1.17 | -0.12 Bn |
| 250 | BDRX | Biodexa Pharmaceuticals Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -6.38 | — | 0.07 Bn |
| 251 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.67 | — | 0.08 Bn |
| 252 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -2.93 | — | 0.05 Bn |
| 253 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -4.09 | — | 0.08 Bn |
| 254 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 0.00 | — | 0.07 Bn |
| 255 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.48 | — | 0.07 Bn |
| 256 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.62 | — | 0.07 Bn |
| 257 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.83 | — | 0.07 Bn |
| 258 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 11.36 | 1.40 | 0.02 Bn |
| 259 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -6.72 | 0.40 | 0.02 Bn |
| 260 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -3.22 | 3.02 | -0.06 Bn |
| 261 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.76 | 14.39 | 0.02 Bn |
| 262 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.43 | 5.09 | 0.05 Bn |
| 263 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.05 | — | 0.05 Bn |
| 264 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.26 | — | 0.05 Bn |
| 265 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -2.64 | 1,417.08 | 0.05 Bn |
| 266 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.59 | 25.98 | 0.05 Bn |
| 267 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.04 | — | 0.05 Bn |
| 268 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.41 | 2.27 | 0.05 Bn |
| 269 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.23 | 3.52 | 0.05 Bn |
| 270 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.17 | 90.45 | 0.05 Bn |
| 271 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 3.87 | 1.25 | 0.04 Bn |
| 272 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.09 Bn |
| 273 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.66 | 294.15 | -0.02 Bn |
| 274 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -4.15 | — | 0.04 Bn |
| 275 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.01 | — | 0.02 Bn |
| 276 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.68 | — | 0.03 Bn |
| 277 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.35 | 294.63 | 0.02 Bn |
| 278 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.57 | — | 0.04 Bn |
| 279 | ALP | Alpha Compute Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.02 | 0.19 | 0.04 Bn |
| 280 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.84 | — | 0.04 Bn |
| 281 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.18 | 0.96 | 0.02 Bn |
| 282 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.72 | 4.79 | 0.03 Bn |
| 283 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.72 | — | 0.03 Bn |
| 284 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -22.20 | — | 0.03 Bn |
| 285 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.16 | 4.24 | 0.03 Bn |
| 286 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -6.19 | 0.38 | 0.03 Bn |
| 287 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 288 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.33 | 37.92 | 0.03 Bn |
| 289 | YDESW | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | — | — | 0.03 Bn |
| 290 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.23 | — | 0.03 Bn |
| 291 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -23.02 | — | 0.03 Bn |
| 292 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -12.26 | 93.50 | 0.03 Bn |
| 293 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.63 | — | 0.03 Bn |
| 294 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.30 | 869.19 | 0.02 Bn |
| 295 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.37 | — | 0.02 Bn |
| 296 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.66 | — | 0.02 Bn |
| 297 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.40 | — | 0.02 Bn |
| 298 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.32 | 2.68 | 0.01 Bn |
| 299 | JSPR | Jasper Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.10 | — | 0.02 Bn |
| 300 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.05 | 261.63 | 0.02 Bn |